Showing results (391-400 of 404) with videos related to
Sort By:
Pageof 41
Recenti Progressi in Medicina|May 22, 2015
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]Salvatore D'Angelo, Domenico Germano, Teresa Zolfino, et al.Plos One|August 30, 2014
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis surveyDaniele Santini, Francesco Pantano, Ferdinando Riccardi, et al.The Oncologist|January 5, 2019
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study SubanalysisClaudio Vernieri, Fabio Galli, Laura Ferrari, et al.Giornale Italiano Di Cardiologia (2006)|October 23, 2020
[HCF-ANMCO/AICPR/GIEC/ITAHFA/SICOA/SICP/SIMG/SIT Cardiological Societies Council Consensus document: Anticoagulant therapy in venous thromboembolism and atrial fibrillation of the patient with cancer. Current knowledge and new evidence]Michele Massimo Gulizia Chairperson, Iris Parrini Co-Chairperson, Furio Colivicchi Co-Chairperson, et al.Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.Oncotarget|September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experiencePatrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.ESMO Open|August 30, 2017
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trialE Martinelli, C Cardone, T Troiani, et al.Pageof 41